Somatic gene therapy for hypertension

Brazilian Journal of Medical and Biological Research

Volumn 33, Issue 6, 2000, Pages 715-721

  Phillips, M I ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Antisense; Gene therapy; Hypertension; Vectors

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; COMPLEMENTARY DNA;

ADENO ASSOCIATED VIRUS; ANIMAL; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; HYPERTENSION; RAT; REVIEW;

ANIMALS; DEPENDOVIRUS; DNA, ANTISENSE; GENE THERAPY; GENETIC VECTORS; HUMANS; HYPERTENSION; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; RATS;

EID: 0034199888     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2000000600013     Document Type: Article

References (17)

1. Kaplan NM (1998). Clinical Hypertension. Williams and Wilkins, Baltimore.
2. Lifton RP (1996). Molecular genetics of human blood pressure variation. Science, 272: 676-680.
3. Zhang YC, Bui JD, Shen LP & Phillips MI (2000). Antisense inhibition of beta-1-adrenoceptor mRNA in a single dose produces a profound and prolonged reduction in high blood pressure in spontaneously hypertensive rats. Circulation, 101: 682-688.
4. Jeunemaitre X, Soubrier F, Kotelevetsev YV, Lifton RP, Williams CS, Chiaru A, Hunt SC, Hopkins PN, Williams RR, Lalouel JM & Corvol P (1992). Molecular basis of human hypertension: role of angiotensinogen. Cell, 71: 169-180.
5. Wielbo D, Simon A, Phillips MI & Toffolo S (1996). Inhibition of hypertension by peripheral administration of antisense oligodeoxynucleotides. Hypertension, 28: 147-151.
6. Makino K, Sugano M, Ohtsuka S & Sawada S (1998). Intravenous injection with antisense oligodeoxynucleotides against angiotensinogen decreases blood pressure in spontaneously hypertensive rats. Hypertension, 31: 1166-1170.
7. 1 angiotensin receptor mRNA in spontaneously hypertensive rats. American Journal of Hypertension, 10: 56S-62S.
8. 1 receptor mRNA in brain and blood. Hypertension, 31: 1317-1323.
9. Tang X, Mohuczy D, Zhang CY, Kimura B, Galli SM & Phillips MI (1999). Systemic delivery of antisense against angiotensinogen mRNA by adeno-associated plasmid vector decreases hypertension. American Journal of Physiology, 277: H2392-2399.
10. Lynch KR, Simnad VI, Ben Ari ET & Garrison JC (1986). Localization of preangiotensinogen messenger RNA sequences in the rat brain. Hypertension, 8: 540-543.
11. Zolotukhin S, Potter M, Hauswirth WW, Guy J & Muzyczka NA (1996). "Humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells. Journal of Virology, 70: 4646-4654.
12. Mohuczy D, Gelband C & Phillips MI (1999). Antisense inhibition of AT1 receptors in vascular smooth muscle cells using adeno-associated virus-based vector. Hypertension, 33: 354-359.
13. Phillips MI (1997) Antisense inhibition and adeno-associated viral vector delivery for reducing hypertension. Hypertension, 29: 177-187.
14. Chao J & Chao L (1997). Kallikrein gene therapy: a new strategy for hypertensive diseases. Immunopharmacology, 36: 229-236.
15. Iyer SN, Lu D, Katovich M & Raizada MK (1996). Chronic control of high blood pressure in the spontaneously hypertensive rats by delivery of angiotensin type 1 receptor antisense. Proceedings of the Na7 tional Academy of Sciences, USA, 93: 9960-9965.
16. Martens JR, Reaves PY, Lu D, Katovich MJ, Berecek KH, Bishop SP, Raizada MK & Gelband CH (1998). Prevention of renvascular and cardiac pathophysiological changes in hypertension by angiotensin II type 1 receptor antisense gene therapy. Proceedings of the National Academy of Sciences, USA, 95: 2664-2669.
17. Phillips MI (1999). Is gene therapy for hypertension possible? Hypertension, 33: 8-13.